title: [Fabry disease--a diagnostic and therapeutic challenge].
abstract: BACKGROUND
  Fabry disease, unlike most other metabolic diseases, is prone to familiar and regional clustering because of X-linked inheritance and normal fertility in affected men. Affected individuals can be offered intravenous enzyme replacement therapy.
  
  
  METHODS
  In two counties in western Norway there are 41 affected individuals, giving a minimum prevalence of the disease of 1 in 17,000. The patient material is briefly presented. We discuss some of the administrative and financial challenges that this type of diseases present in our public health system.
  
  
  CONCLUSIONS
  The great variability in disease expression and severity within and between families delays the diagnosis and necessitates a broad clinical follow up of affected persons. A false diagnosis is often made (e.g. MS, irritable colon, a psychiatric disorder, idiopathic hypertrophic cardiomyopathy, or kidney failure). The follow up regime is briefly described, with special emphasis on the practical and financial implications of enzyme replacement therapy in Norway.
authors.affiliation: Kompetansesenteret for Fabry sykdom, Senter for medisinsk genetikk og molekylaermedisin, Haukeland Universitetssjukehus, 5021 Bergen. gunnar.houge@helse-bergen.no
authors.forename: Gunnar
authors.initials: G
authors.lastname: Houge
authors.forename: Alv Johan
authors.initials: AJ
authors.lastname: Skarbøvik
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D017281:Cost of Illness; D016527:Drug Costs; D000795:Fabry Disease / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D009664:Norway / Q000453:epidemiology; D000519:alpha-Galactosidase / Q000008:administration & dosage / Q000191:economics
chemical_list: D000519:alpha-Galactosidase